Cyclo Therapeutics Set to Shine at the Upcoming WORLDSymposium
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) is excited to announce that it will be showcasing its innovative research during the upcoming 21st Annual WORLDSymposium™. This esteemed event will take place from February 3-7, 2025, in San Diego, providing a platform for the most recent advancements in lysosomal diseases research.
Conference Presentations Overview
The company is proud to inform that two of its abstracts have been accepted for both oral and poster presentations. The details for these significant presentations are carefully structured to ensure that the most vital information reaches the audience.
Oral Presentation Details
One of the highlights will be an oral presentation titled Trappsol Cyclo™: Open Label Treatment in the TransportNPC™ Sub-Study in Patients Under the Age of 3 Diagnosed with Niemann-Pick Disease Type C1. This will be presented by Ronen Spiegel, MD, who holds a prominent position as Clinical Associate Professor and Director at Emek Medical Center. The session titled Clinical Applications is scheduled for Thursday, February 6, 2025, at 1:30 PM PT.
Poster Presentations
Cyclo Therapeutics will also feature poster presentations that detail their groundbreaking approach and findings. Firstly, the poster named Trappsol Cyclo™ (HP?CD) for the Long-Term Treatment of Niemann-Pick Type C1: Efficacy and Safety Data from 4 Clinical Studies and the Ongoing Expanded Access Program will be led by Dr. Caroline Hastings, a respected pediatric hematologist oncologist. This is part of the Clinical Applications & Rapid-Fire – Poster Session III, occurring on the same day, February 6, 2025, from 3:30 PM to 5:30 PM PT.
Additionally, Dr. Hastings will also present another poster titled Trappsol Cyclo™ and NPC: Efficacy Shown Across Individual 5D Domains and the Utilization of Future Assessment Tools to Demonstrate Clinically Relevant Outcomes during the Rapid-Fire Poster Session III, further amplifying the company's commitment to addressing the intricacies of Niemann-Pick Disease Type C1.
About WORLDSymposium™
WORLDSymposium™ serves as a critical annual conference dedicated to advancing research, particularly towards lysosomal diseases. This event is a collaboration amongst a global network of over 2000 researchers from 50 countries, all united by a commitment to uncovering new insights into these complex conditions.
About Cyclo Therapeutics
Cyclo Therapeutics is at the forefront of clinical-stage biotechnology, committed to innovating and developing medicines aimed at transforming patients' lives. Their flagship product, Trappsol Cyclo™, has been designated as an orphan drug in both the United States and Europe, focusing on Niemann-Pick Disease Type C1. The company boasts four ongoing formal clinical trials addressing this rare and severe genetic illness.
In addition, Cyclo Therapeutics is also exploring solutions for early Alzheimer's disease through ongoing Phase 2b clinical trials for Trappsol Cyclo™. These efforts stem from positive results obtained in an Expanded Access program, highlighting the potential for broader applications of their therapeutic compounds.
The company is also innovating in the realms of new indications for their products, consistently aiming to expand the spectrum of therapeutic options available to patients.
Frequently Asked Questions
What is the focus of Cyclo Therapeutics at WORLDSymposium?
Cyclo Therapeutics will highlight research on Trappsol Cyclo™ for treating Niemann-Pick Disease Type C1 through oral and poster presentations.
When is the conference taking place?
The 21st Annual WORLDSymposium™ will be held from February 3-7, 2025, in San Diego.
Who will present at the conference for Cyclo Therapeutics?
Ronen Spiegel, MD, and Dr. Caroline Hastings will represent Cyclo Therapeutics during the presentations.
What is Trappsol Cyclo™?
Trappsol Cyclo™ is an orphan drug aimed at treating Niemann-Pick Disease Type C1, with ongoing clinical trials supporting its efficacy.
Is Cyclo Therapeutics involved in other research areas?
Yes, Cyclo Therapeutics is also conducting trials for early Alzheimer's disease and exploring additional indications beyond Niemann-Pick Disease Type C1.
